论文部分内容阅读
目的:评价生物反应调节剂(BRM)经肝动脉化疗栓塞术(TACE)治疗ACI大鼠肝细胞癌的疗效。方法:在30只雄性ACI大鼠肝包膜下植入Morris Hepatom 3924A肝癌瘤块(2 mm3),移植术后13天行MRI检查,测量肿瘤体积V1;第14天时,经腹部切开术及胃十二指肠动脉逆行插管而采取以下3种介入治疗方案:①A组,0.1 mg丝裂霉素、0.1 ml碘油、7.5μg TNFα和5×103IU IL-2(n=10);②B组,0.1 mg丝裂霉素、0.1 ml碘油、0.05 mg链球菌提取物(OK-432)和5×103IU IL-2(n=10);③C组(对照组),0.1 mg丝裂霉素、0.1 ml碘油(n=10);13天后再次行MRI检查以确定肿瘤体积V2变化。比较肝肿瘤体积生长率V2/V1。结果:肿瘤治疗前和治疗后体积分别为A组0.0377 cm3和0.2752 cm3;B组0.0344 cm3和0.2233 cm3;C组0.0380 cm3和0.3398 cm3。介入治疗后肿瘤体积与治疗前肿瘤体积之比(V2/V1)分别为A组7.31、B组6.53、C组9.14。与对照组相比,采取A组的治疗方案能抑制肝肿瘤体积的生长(P=0.042),采取B组的治疗方案能明显抑制肿瘤的生长(P=0.004)。结论:采取免疫化疗栓塞术能有效抑制ACI大鼠肝细胞癌的生长。
PURPOSE: To evaluate the efficacy of biological response modifier (BRM) in the treatment of hepatocellular carcinoma (ACI) in rats by transcatheter arterial chemoembolization (TACE). Methods: Morris Hepatom 3924A hepatoma tumor mass (2 mm 3) was implanted into the liver of 30 male ACI rats. MRI examination was performed 13 days after the transplantation to determine the tumor volume V1. On the 14th day, Gastroduodenal artery retrograde intubation and take the following three kinds of interventional treatment programs: ①A group, 0.1 mg mitomycin, 0.1 ml lipiodol, 7.5μg TNFα and 5 × 103IU IL-2 (n = 10); ② B 0.1 mg mitomycin, 0.1 ml lipiodol, 0.05 mg Streptococcus extract (OK-432) and 5 × 10 3 ILU-2 (n = 10) 0.1 ml Lipiodol (n = 10); MRI was performed again 13 days later to determine the change in tumor volume V2. Compare the volume growth rate of liver tumor V2 / V1. Results: Before treatment and after treatment, the volume of tumor was 0.0377 cm3 and 0.2752 cm3 in group A, 0.0344 cm3 and 0.2233 cm3 in group B, 0.0380 cm3 and 0.3398 cm3 in group C, respectively. The ratio of tumor volume to tumor volume before treatment (V2 / V1) was 7.31 in group A, 6.53 in group B and 9.14 in group C, respectively. Compared with the control group, the treatment of group A could inhibit the growth of liver tumor volume (P = 0.042), and the treatment of group B could significantly inhibit tumor growth (P = 0.004). Conclusion: Immunochemotherapy and embolization can effectively inhibit the growth of hepatocellular carcinoma in ACI rats.